Vandana Singh
·
August 12, 2025
Benzinga
Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.
read more
November 7, 2025
September 5, 2025
August 27, 2025
Bloomberg
August 15, 2025
Barchart
August 31, 2025
Financial Times